CN108586445A - Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension - Google Patents
Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension Download PDFInfo
- Publication number
- CN108586445A CN108586445A CN201810560186.4A CN201810560186A CN108586445A CN 108586445 A CN108586445 A CN 108586445A CN 201810560186 A CN201810560186 A CN 201810560186A CN 108586445 A CN108586445 A CN 108586445A
- Authority
- CN
- China
- Prior art keywords
- endothelin
- amide derivatives
- cerebrovascular
- cardiovascular
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 0 CC(C)(C1*S(NC(c2cc(O)n[o]2)=O)(=O)=O)Oc2cc(OC)ccc2C1c(cc1)cc2c1c(CCC=C1)c1[s]2 Chemical compound CC(C)(C1*S(NC(c2cc(O)n[o]2)=O)(=O)=O)Oc2cc(OC)ccc2C1c(cc1)cc2c1c(CCC=C1)c1[s]2 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
A kind of application the invention discloses amide derivatives formula I and its as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension,Wherein:R1、R2It is independently selected from H, F, OH or CH3.It finds that amide derivatives formula I of the present invention has preferable endothelin receptor antagonizing activity in the contraction experiment for inhibiting Endothelin to induce isolated rabbit aortic annulus, can be used to prepare that treat cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetic complication, nephrosis, asthma and thyroid gland hyperfunction etc. as endothelin-receptor antagonists.
Description
Technical field
The invention belongs to chemical medicine, it is related to a kind of amide derivatives formula I and its as endothelin receptor antagonism
Application of the agent in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension.
Background technology
Cardiovascular and cerebrovascular disease (cardiovascular and cerebrovascular diseases, CCVd) is heart
The general designation of blood vessel and cranial vascular disease refers to hyperlipidemia, blood is sticky, caused by atherosclerosis, hypertension etc.
Heart, brain and the body tissue ischemic or hemorrhagic disease that occur.The death rate of cardiovascular and cerebrovascular disease occupies various diseases
First of, the final cause of the death overwhelming majority is myocardial hypertrophy, heart failure, cerebral apoplexy and fatal arrhythmia.Especially in recent years
The case fatality rate of serious heart failure is high, has formed a problem of international the world of medicine.These diseases lack effective at present
Medicine.
Endothelin (endothelin, ET) be made of 21 amino acid discoveries such as Yanagisawa within 1988 it is more
Peptide is synthesized and is secreted by vascular endothelial cell, cardiac muscle, smooth muscle etc., belongs to sarafotoxin (sarafotoxin) family, has
Powerful contracting blood vessel and rush vascular smooth muscle cells, is a kind of endogenous damage factor, in many hearts, brain, lung, kidney
It is all of great significance in the morbidity of vascular diseases.ET has the shaped body of 3 kinds of forms, is referred to as ET-1, ET-2 and E-3,
ET is acted on through Endothelin-converting Enzyme (ECEs) and activate, the ET of activation and its receptor in conjunction with and play a role, wherein ET1 is existing by force
Strong and lasting vasoconstrictor effects, and be the inflammatory for causing a variety of diseases with cell growth and mitosis characteristic is promoted
The factor.Due to the potential therapeutic value that endothelin antagonist is contained, major drugmaker of the world all energetically puts into endothelium
In the research and development of plain antagonist, the research of endothelin antagonist has become hot spot.The stronger peptides of effect having found
ET antagonists have BQ123, BQ160, FR2139317 etc., but are limited since the oral bioavailability rate of peptide agonist is low
Its application in the angiocardiopathy of palpus long-term administration.Many drugmakers are dedicated to the non-peptides ET antagonisms for having Orally active
The research of agent.The endothelin-receptor antagonists listed have Bosentan, tezosentan, enrasentan, sitaxentan, A Qusheng
Smooth and ambrisentan, in treatment hypertension, pulmonary hypertension, tumour, diabetic complication, myocardial infarction and cerebral angiospasm etc.
Aspect obtains very good effect.
Used in test example of the present invention control drug Bosentan chemical structural formula for:
Invention content
The invention discloses a kind of amide derivatives formula I, structure is:
Wherein:R1、R2It is independently selected from H, F, OH or CH3.The invention further relates to
The pharmaceutically acceptable salt or solvate of the amide derivatives formula I.
Further, amide derivatives formula I described in some preferred schemes is
The synthetic route that another object of the present invention discloses the amide derivatives formula I is:
Specifically synthetic method is:
1) 3- sulfamoyls propionic acid (compound 1) occurs into the presence of a base with 2,4- dihydroxy-benzoic acids (compound 2)
Ring reacts, and generates (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 3);
2) in a suitable solvent, compound 3 reacts with iodomethane, generates (7- methoxyl group -2- oxo -2H- colors
Alkene -3- bases) Methanesulfomide (compound 4);
3) in a suitable solvent, compound 4 and iodide react generation (7- methoxyl groups -2,2- dimethyl -
2H- chromene -3- bases) Methanesulfomide (compound 5);
4) compound 5 again with hexichol [b, d] thiophene reaction generate (4- (hexichol [b, d] thiene-3-yl) methoxyl group-2-7-,
2- lutidines -3- bases) Methanesulfomide (compound 6);
5) in a suitable solvent, compound 6 and corresponding acyl chloride reaction, generate corresponding amide product.
Further, the alkali of the use in the step 1) can use potassium carbonate, and cesium carbonate, triethylamine, sodium hydroxide is molten
Liquid or potassium hydroxide solution, sodium carbonate liquor, preferably triethylamine.
Further, the solvent in the step 2) can use n,N-Dimethylformamide (DMF), Dioxane, DMSO,
DMF, acetone etc., preferably acetone;
Further, the solvent in the step 3) can use n,N-Dimethylformamide (DMF), Dioxane, DMSO,
DMF, THF, acetone etc., preferably THF.
Further, solvent can be absolute ethyl alcohol, second eyeball, benzene, toluene, dimethylbenzene, ether, diformazan in the step 5)
Base sulfoxide, n,N-Dimethylformamide (DMF), acetone, pyridine etc., preferably absolute ethyl alcohol.
Another object of the present invention discloses application of the amide derivatives formula I as endothelin-receptor antagonists.
With the relevant disease of endothelin-receptor antagonists such as cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetes
Complication, nephrosis, asthma and thyroid gland are hyperfunction etc..
Pharmaceutically acceptable salt of the present invention refers to the organic salt and inorganic salts of the compounds of this invention.Pharmaceutically may be used
The salt that the nontoxic acid received is formed includes, but is not limited to, inorganic acid salt, such as hydrochloride, hydrobromate, phosphate, sulfuric acid
Salt, perchlorate;Acylate, such as acetate, oxalates, maleate, tartrate, citrate, succinate, the third two
Hydrochlorate;Or these salt are obtained by other methods described in the books or literature such as ion-exchange.Other can pharmaceutically connect
The salt received includes adipate, alginates, ascorbate, aspartate, benzene sulfonate, benzoate, bisulphate,
Borate, butyrate, camphor hydrochlorate, camsilate, cyclopentyl propionate, digluconate, lauryl sulfate, second
Sulfonate, formates, fumarate, gluceptate, glycerophosphate, gluconate, Hemisulphate, enanthate,
Caproate, hydriodate, 2- hydroxy-ethanesulfonate salts, lactobionate, lactate, laruate, lauryl sulfate, apple
Hydrochlorate, mesylate, 2- naphthalene sulfonates, nicotinate, nitrate, oleate, palmitate, pamoate, pectate, persulfuric acid
Salt, 3- phenylpropionic acid salt, picrate, pivalate, propionate, stearate, rhodanate, tosilate, 11
Hydrochlorate, valerate, etc..By including alkali metal, alkaline-earth metal, ammonium and N+ (C1-4 alkane with alkali appropriate salt obtained by the reaction
Base) 4 salt.Water-soluble or oil-soluble or dispersion product can be obtained by quaternization.Can with the alkali metal of forming salt or
Alkaline-earth metal includes sodium, lithium, potassium, calcium, magnesium, etc..Pharmaceutically acceptable salt further comprises appropriate, nontoxic ammonium, season
The amine cation that ammonium salt and gegenions are formed, such as halide, hydroxide, carboxylate, hydrosulphate, phosphoric acid compound, nitre
Acidulants, C1-8 azochlorosulfonate acid compounds and aromatic sulphonic acid compound.
Solvate of the present invention refers to that one or more solvent molecules are formed by with the compound of the present invention and form
Close object.The solvent for forming solvate includes, but is not limited to, water, isopropanol, ethyl alcohol, methanol, dimethyl sulfoxide, ethyl acetate,
Acetic acid and ethylaminoethanol.
Specific implementation mode
Embodiment 1:N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first
Base) sulfonyl) isoxazole -5- formamides synthesis
The synthesis of 1-1, (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide
By 3- sulfamoyls propionic acid (compound 1) (15.0g, 97.94mmol) and 2,4- dihydroxy-benzoic acids (compound 2)
(10.2g, 66.18mmol) is dissolved in acetic anhydride (22.6mL), the careful addition triethylamine (13.2mL) into mixture, and
Mixture is heated 4 hours.After having reacted, cooling is simultaneously diluted with water.The product of precipitation is filtered and is washed with methanol aqueous solution,
Obtain (7- hydroxyl -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 3), 21.2g, yield 85%.1H-NMR
(400MHz,CDCl3)δ:4.08(s,2H),5.14(s,2H),5.26(s,1H),6.74(s,1H),6.81(d,1H),7.51
(dd,1H),7.60(s,1H).13C-NMR(125MHz,CDCl3)δ:63.62,102.58,112.85,114.47,119.70,
129.31,140.10,156.42,157.32,160.10.LC-MS(ESI,pos,ion)m/z:256[M+H].
The synthesis of 1-2, (7- methoxyl group -2- oxo -2H- chromene -3- bases) Methanesulfomide
At room temperature, in the presence of Anhydrous potassium carbonate (6.3g, 45.58mmol), with being dissolved in acetone (50.0mL)
Methyl iodide (4.0mL) solution and compound 3 (21.2g, 83.06mmol) are reacted one hour, and concentrated solvent is beaten with water, filtering,
Obtain (7- methoxyl group -2- oxo -2H- chromene -3- bases) Methanesulfomide (compound 4), 12.0g, yield 98%.1H-NMR
(400MHz,CDCl3)δ:3.84(s,3H),4.08(s,2H),5.87(s,2H),7.01(dd,1H),7.04(s,1H),7.58
(s,1H),7.68(dd,1H).13C-NMR(125MHz,CDCl3)δ:56.08,63.62,101.23,112.76,113.78,
119.70,128.73,140.10,156.59,157.32,162.49.LC-MS(ESI,pos,ion)m/z:270[M+H].
The synthesis of 1-3, (7- methoxyl group -2,2- dimethyl -2H- chromene -3- bases) Methanesulfomide
Using THF as solvent, compound 4 (12.0g, 44.56mmol) is made to occur with iodide (13g, 78.20mmol)
Reaction flows back 4 hours, and after the completion of reaction, reaction, concentrated solvent, flash column chromatography separation, you can obtain yellow is quenched in acid adding
Solid (7- methoxyl group -2,2- dimethyl -2H- chromene -3- bases) Methanesulfomide (compound 5), 10.5g, yield 83%.1H-NMR(400MHz,CDCl3)δ:1.45(s,6H),3.84(s,3H),4.08(s,2H),4.29(s,2H),6.43(s,1H),
6.65(dd,1H),7.18(s,1H),7.91(dd,2H).13C-NMR(125MHz,CDCl3)δ:27.07,56.08,62.25,
74.02,103.68,105.06,113.29,119.81,124.15,128.02,155.91,161.96.LC-MS(ESI,pos,
ion)m/z:284[M+H].
The conjunction of 1-4, (4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) Methanesulfomide
At
Compound 5 (10.5g, 37.06mmol) is dissolved in anhydrous dichloroethylene (10mL), and is stirred continuously, at 5 DEG C
Under, anhydrous Aluminum chloride (15.0g, 112.5mmol) is added into the solution of above-mentioned stirring, after stirring 0.5 hour, hexichol is added
[b, d] thiophene (182.3mmol) simultaneously stirs mixture 12 hours at 50-60 DEG C.It is then added into ice and concentrated hydrochloric acid
In the mixture of (13mL) to quench the reaction.It is extracted again by organic layer separation and by water layer with dichloromethane (2*25mL).It will close
And extract washed with sodium bicarbonate (50mL), dried with anhydrous sodium sulfate, filter and evaporate.Obtained crude on silica gel
Chromatography obtains thick liquid (4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) Methanesulfomide
(compound 6), 14.21g, yield 82%.1H-NMR(400MHz,CDCl3)δ:1.36(s,6H),3.21(dd,1H),3.46
(dd,1H),3.59(dt,1H),3.84(s,5H),4.51(d,1H),6.53-6.57(m,2H),7.24-7.31(m,3H),
7.56(td,1H),7.77(d,1H),7.86(dd,1H),8.03(d,1H),8.45(dd,1H).13C-NMR(125MHz,
CDCl3)δ:25.75,47.5,50.49,53.73,56.08,77.15,103.64,105.65,117.38,119.13,
123.45,124.32,124.34,124.54,127.02,127.42,128.3,133.41,134.51,138.41,139.2,
140.4,154.65,161.83.LC-MS(ESI,pos,ion)m/z:468[M+H].
1-5, N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulphur
Acyl group) isoxazole -5- formamides synthesis
Compound 6 (14.21g, 30.39mmol) is added in absolute ethyl alcohol (150mL), different evil is then gradually added into
Azoles -5- formyl chlorides (35mmol), stirring are warming up to reaction reflux.It reacts and finishes after about 8 hours, TLC monitors reaction end.It will be anti-
Answer liquid stand it is cooling after, filter, a small amount of absolute ethyl alcohol be used in combination to wash filter cake, obtain white solid product N- (((4- (hexichol [b,
D] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl) isoxazole -5- formamides, 15.73g,
Yield 92%.1H-NMR(400MHz,CDCl3)δ:1.36(s,6H),3.21(m,1H),3.46-3.52(m,2H),3.84(s,
3H),4.51(d,1H),6.00(d,1H),6.53-6.57(m,3H),7.24-7.31(m,3H),7.56(td,1H),7.77(d,
1H),7.86(dd,1H),8.16(d,1H),8.29(d,1H),8.45(dd,1H).13C-NMR(125MHz,CDCl3)δ:
25.75,47.5,52.81,54.09,56.08,77.15,103.64,105.65,108.06,117.38,119.13,123.45,
124.32,124.34,124.54,127.02,127.42,128.3,133.41,134.51,138.41,139.2,140.4,
141.68,153.55,154.65,161.79,161.83.LC-MS(ESI,pos,ion)m/z:563[M+H]。
Embodiment 2:N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first
Base) sulfonyl)-(the fluoro- isoxazoles of 3-) -5- formamides synthesis
Compound 6 (14.21g, 30.39mmol) is added in absolute ethyl alcohol (150mL), is then gradually added into that (3- is fluoro-
Isoxazole) -5- formyl chlorides (35mmol), stirring, which is warming up to, reacts reflux.It reacts and finishes after about 8 hours, TLC monitorings reaction is eventually
Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4-
(hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl)-(the fluoro- isoxazoles of 3-) -
5- formamides, 16.59, yield 94%.LC-MS(ESI,pos,ion)m/z:581[M+H].
Embodiment 3:N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first
Base) sulfonyl)-(3- hydroxyls-isoxazole) -5- formamides synthesis
Compound 6 (14.21g, 30.39mmol) is added in absolute ethyl alcohol (150mL), (3- hydroxyls are then gradually added into
Base-isoxazole) -5- formyl chlorides (35mmol), stirring, which is warming up to, reacts reflux.It reacts and finishes after about 8 hours, TLC monitoring reactions
Terminal.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4-
(hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl)-(3- hydroxyls-different evil
Azoles) -5- formamides, 16.00g, yield 91%.LC-MS(ESI,pos,ion)m/z:579[M+H].
Embodiment 4:N- (((4- (hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) first
Base) sulfonyl)-(3- methyl-isoxazole) -5- formamides synthesis
Compound 6 (14.21g, 30.39mmol) is added in absolute ethyl alcohol (150mL), (3- first is then gradually added into
Base-isoxazole) -5- formyl chloride 35mmol), stirring is warming up to reaction reflux.It reacts and finishes after about 8 hours, TLC monitorings reaction is eventually
Point.It after reaction solution is stood cooling, filters, a small amount of absolute ethyl alcohol washing filter cake is used in combination, obtains white solid product N- (((4-
(hexichol [b, d] thiene-3-yl) -7- methoxyl group -2,2- lutidines -3- bases) methyl) sulfonyl)-(3- methyl-different evil
Azoles) -5- formamides, 14.89g, yield 85%.LC-MS(ESI,pos,ion)m/z:577[M+H].Test example 1:Inhibit endothelium
The contraction of element induction isolated rabbit aortic annulus
Normal rabbits auricular vein pneumatic needl opens chest after putting to death, take out aorta pectoralis, separation.It is placed in 4 containing saturated oxygen
Connective tissue is removed in DEG C cold K-H liquid.Gently rubbed removal endarterium epithelial cell with cotton thread.It is cut into the vascular circle of 4-6mm,
It hangs in the 8mL baths containing K-H buffer salt solutions, leads to pure O2, pH7.4,37 DEG C of constant temperature.Adjusting rest tension is 2g, balance
60min。
ET-1 (10 is added-8Mol/L final concentrations), 40min is incubated when vessel retraction reaches maximum tension, administration group difference
Test-compound (10 is added-6Mol/L final concentrations), if solvent group is control.Observe its vessel retraction to Endothelin in 40min
The antagonism of reaction.The calculating of endothelin antagonist inhibiting rate:ET-1 to vessel retraction 40min when tension be A (g),
Test-compound (10-6Mol/L final concentrations) be incubated 40min after vessel retraction tension be B (g), then its inhibit percentage be (A-
B)/A × 100%.(N=6)
Table 1ERA induces rabbit myocardium vessel tension variation to ET-1
Amide derivatives formula I of the present invention has preferable endothelin receptor antagonizing activity, can be used as Endothelin
Receptor antagonist be used to prepare treatment cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, myocardial infarction, tumour, diabetic complication,
Nephrosis, asthma and thyroid gland are hyperfunction etc..
Claims (5)
1. a kind of general formula structure is the amide derivatives and its pharmaceutically acceptable salt or solvate of formula I
Wherein:R1、R2It is independently selected from H, F, OH or CH3。
2. amide derivatives formula I as described in claim 1, characterized in that be selected from following compound:
3. application of the amide derivatives formula I as claimed in claim 1 or 2 as endothelin-receptor antagonists.
4. application of the amide derivatives formula I as claimed in claim 1 or 2 in the drug for preparing cardiovascular and cerebrovascular disease.
5. amide derivatives formula I as claimed in claim 1 or 2 is preparing cardiovascular and cerebrovascular, hypertension, pulmonary hypertension, the heart
Application in the hyperfunction drug of flesh infarct, tumour, diabetic complication, nephrosis, asthma, thyroid gland.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810560186.4A CN108586445A (en) | 2018-06-03 | 2018-06-03 | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810560186.4A CN108586445A (en) | 2018-06-03 | 2018-06-03 | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108586445A true CN108586445A (en) | 2018-09-28 |
Family
ID=63630865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810560186.4A Withdrawn CN108586445A (en) | 2018-06-03 | 2018-06-03 | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108586445A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050096329A1 (en) * | 2003-10-14 | 2005-05-05 | Boy Kenneth M. | 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants |
JP2005131365A (en) * | 2003-08-11 | 2005-05-26 | Depuy Mitek Inc | Tissue repair implant |
WO2015021134A2 (en) * | 2013-08-06 | 2015-02-12 | University Of South Florida (A Florida Non-Profit Corporation) | Target binding molecules identified by kinetic target-guided synthesis |
CN106687465A (en) * | 2014-06-11 | 2017-05-17 | 维纳拓尔斯制药公司 | Beta-lactamase inhibitors |
CN107759652A (en) * | 2017-08-30 | 2018-03-06 | 大连理工大学 | Containing cholesteric coumarin derivatives and its synthesis and application |
-
2018
- 2018-06-03 CN CN201810560186.4A patent/CN108586445A/en not_active Withdrawn
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005131365A (en) * | 2003-08-11 | 2005-05-26 | Depuy Mitek Inc | Tissue repair implant |
US20050096329A1 (en) * | 2003-10-14 | 2005-05-05 | Boy Kenneth M. | 3-Thia-4-arylquinolin-2-one derivatives as smooth muscle relaxants |
WO2015021134A2 (en) * | 2013-08-06 | 2015-02-12 | University Of South Florida (A Florida Non-Profit Corporation) | Target binding molecules identified by kinetic target-guided synthesis |
CN106687465A (en) * | 2014-06-11 | 2017-05-17 | 维纳拓尔斯制药公司 | Beta-lactamase inhibitors |
CN107759652A (en) * | 2017-08-30 | 2018-03-06 | 大连理工大学 | Containing cholesteric coumarin derivatives and its synthesis and application |
Non-Patent Citations (1)
Title |
---|
FILIPE AREIAS 等: "New chromene scaffolds for adenosine A2A receptors: Synthesis, pharmacology and structureeactivity relationships", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102187608B1 (en) | SSAO inhibitor | |
CN105085322B (en) | The Preparation Method And Their Intermediate of the intermediates of AHU 377 and the preparation method of intermediate | |
CN104245663B (en) | bicyclic compound | |
NO341930B1 (en) | Crystalline forms of 4-methyl-N- [3- (4-methylimidazol-1-yl) -5-trifluoromethylphenyl] -3- (4-pyridin-3-ylpyrimidin-2-ylamino) benzamide | |
CA2693552A1 (en) | Pyridone compound | |
JPH02138262A (en) | Novel medically-active 1,2,3,4,4a,5,10,10a- octahydro-benzo(g)quinoline derivative | |
CN111440145A (en) | Novel crystal form of high-purity trelagliptin and preparation method thereof | |
US6610718B2 (en) | Processes for making- and a new crystalline form of- leflunomide | |
CN110283122B (en) | Preparation method of high-purity Lunvatinib and salt thereof | |
CN108570055A (en) | A kind of amide derivatives and its application in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
CN108586445A (en) | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
CN108658958A (en) | A kind of amide derivatives and its application as endothelin-receptor antagonists | |
CN108570056A (en) | A kind of amide derivatives and its application in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
CN108586472A (en) | Amide derivatives and its application as endothelin-receptor antagonists in the diseases such as cardiovascular and cerebrovascular, pulmonary hypertension | |
JPH07267954A (en) | New 3-phenylsulfonyl-3,7-diazabicyclo(3,3,1)nonane compound,its production, and antiarrhythmic agent | |
CN113956198A (en) | Impurity of roxasistat, preparation method and application thereof | |
CN106588888A (en) | High-purity L-sunitinib malate preparation method | |
JP3213576B2 (en) | Substituted pyridine | |
CN111039880A (en) | Application of miconazole and derivative thereof as TGR5 agonist | |
JP2002540100A (en) | Process for producing 3S-3-amino-3-arylpropionic acid and derivatives thereof | |
NO781896L (en) | 4-PHENYL-8-AMINO-TETRAHYDROISOCHINOLINS, PHARMACEUTICAL PREPARATIONS CONTAINING THESE, PROCEDURES FOR THE PREPARATION OF THESE PREPARATIONS AND THEIR USE AS ANTI-PREPARATIONS | |
NO752109L (en) | ||
CA1327582C (en) | 1,4-dihydropyridine derivative named (-){[(amino-2 ethoxy)-2 ethoxy] methyl}-2 (dichloro-2,3 phenyl)-4 ethoxycarbonyl-3 methoxycarbonyl-5 methyl-6 dihydro-1,4 pyridine; process for preparing the same and pharmaceutical compositions containing said derivative | |
CN117229259B (en) | 8-quinoline sulfonamide phenylimidazole compound and application thereof | |
CN111057069B (en) | Cyclic compound, application and composition thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WW01 | Invention patent application withdrawn after publication |
Application publication date: 20180928 |
|
WW01 | Invention patent application withdrawn after publication |